Existing evidence from randomized controlled trials does not support routine population screening for prostate cancer, a new study concludes. However, a second study suggests that a single test at age 60 could identify men who are most likely to develop and die from prostate cancer. These men could then be monitored more closely, while others could be exempt from further screening.